Literature DB >> 18166262

Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study.

Maximilian Burger1, Madelon N M van der Aa, Johanna M M van Oers, Anke Brinkmann, Theodorus H van der Kwast, Ewout C Steyerberg, Robert Stoehr, Wim J Kirkels, Stefan Denzinger, Peter J Wild, Wolf F Wieland, Ferdinand Hofstaedter, Arndt Hartmann, Ellen C Zwarthoff.   

Abstract

OBJECTIVES: The clinical management of non-muscle-invasive urothelial cell carcinoma of the bladder (UCC) is challenging, as it has a marked tendency to recur and to progress. Aim of this study was to investigate the prognostic value of the WHO 1973 and 2004 grading systems and biomarkers FGFR3, CK20 and Ki-67.
METHODS: In a prospective study, tumours from 221 patients were studied for the expression of CK20 and Ki-67 by immunohistochemistry, and FGFR3 status by SNaPshot mutation detection. Staging and grading were performed according to the WHO classification systems of 1973 and 2004.
RESULTS: : Median follow-up was 35 mo. Recurrence occurred in 72 of 221 patients. None of the parameters was able to predict disease recurrence. CK20, Ki-67, FGFR3 mutation, molecular grade using FGFR3 mutation analysis and Ki-67, and histological grading and staging were significantly associated with disease progression in stage. In multivariable analyses, WHO 1973 and 2004 grading systems remained statistically significant and independent predictors of progression, with p=0.005 for WHO 1973 and p=0.004 for 2004. FGFR3 status was able to discriminate progressors from nonprogressors in a subset of patients with high-grade UCC (p=0.009).
CONCLUSIONS: This is the first prospective study comparing the WHO 1973 and 2004 grading systems. We show that both grading systems contribute valuable independent information. Therefore, it should be considered whether a better grading system could be developed that incorporates essential elements from both. The combination of WHO 2004 grading with FGFR3 status allows a better risk stratification for patients with high-grade non-muscle-invasive UCC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18166262     DOI: 10.1016/j.eururo.2007.12.026

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  42 in total

Review 1.  Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer.

Authors:  Ashish M Kamat; J Alfred Witjes; Maurizio Brausi; Mark Soloway; Donald Lamm; Raj Persad; Roger Buckley; Andreas Böhle; Marc Colombel; Joan Palou
Journal:  J Urol       Date:  2014-03-25       Impact factor: 7.450

2.  The role of WNT signalling in urothelial cell carcinoma.

Authors:  I Ahmad
Journal:  Ann R Coll Surg Engl       Date:  2015-08-14       Impact factor: 1.891

Review 3.  Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC).

Authors:  Courtney Pollard; Steven C Smith; Dan Theodorescu
Journal:  Expert Rev Mol Med       Date:  2010-03-25       Impact factor: 5.600

4.  MCM2 and MCM5 as prognostic markers in colon cancer: a worthwhile approach.

Authors:  Maximilian Burger
Journal:  Dig Dis Sci       Date:  2008-08-21       Impact factor: 3.199

5.  Bladder cancer: Progress in defining progression in NMIBC.

Authors:  Michael Gierth; Maximilian Burger
Journal:  Nat Rev Urol       Date:  2013-11-26       Impact factor: 14.432

6.  Chromosome 4p16.3 variant modify bladder cancer risk in a Chinese population.

Authors:  Meilin Wang; Haiyan Chu; Fu Yan; Chao Qin; Pu Li; Lin Yuan; Changjun Yin; Jianfeng Xu; Zhengdong Zhang
Journal:  Carcinogenesis       Date:  2011-03-31       Impact factor: 4.944

Review 7.  Landmarks in non-muscle-invasive bladder cancer.

Authors:  Laura S Mertens; Yann Neuzillet; Simon Horenblas; Bas W G van Rhijn
Journal:  Nat Rev Urol       Date:  2014-07-01       Impact factor: 14.432

Review 8.  [Status of the availability and use of next generation sequencing (NGS) in bladder cancer-a questionnaire within the uropathology working group].

Authors:  N Ortiz-Brüchle; M Muders; M Toma; I Esposito; A Hartmann; R Stöhr; H Reis; P Wild; J Köllermann; F Bremmer; J Leichsenring; A Stenzinger; S Merkelbach-Bruse; S Kirfel; S Perner; N Hartmann; W Roth; A Jung; T Kirchner; K Schwamborn; N Pfarr; E Dahl; R Knüchel; N T Gaisa
Journal:  Urologe A       Date:  2020-03       Impact factor: 0.639

9.  Expression of fibroblast growth factor receptor 3 in the recurrence of non-muscle-invasive urothelial carcinoma of the bladder.

Authors:  Young-Hee Maeng; Su-Yong Eun; Jung-Sik Huh
Journal:  Korean J Urol       Date:  2010-02-18

10.  Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes.

Authors:  Irene Lurkin; Robert Stoehr; Carolyn D Hurst; Angela A G van Tilborg; Margaret A Knowles; Arndt Hartmann; Ellen C Zwarthoff
Journal:  PLoS One       Date:  2010-01-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.